Alumis shares fell 55% after envudeucitinib missed every endpoint in a mid-stage systemic lupus study - and the CEO still sees a path to Phase 3 built on a prespecified interferon-high subgroup. We unpack what that pivot costs and why the whole TYK2 class is now a show-me story outside psoriasis. Also: Roche pays Simcere Zaiming $75 million upfront in a deal worth up to $1.53 billion for trispecific CD79a/CD19/CD3 antibody SIM0660, and Novartis's Rhapsido (remibrutinib) clears two Phase 3 multiple sclerosis trials with no Hy's Law liver cases - the signal that sank Sanofi's tolebrutinib. Plus Kazia Therapeutics reports paxalisib cutting tumor burden 52% in immunotherapy-resistant MSS/pMMR colorectal cancer models ahead of a five-arm Phase 2.


Alex Mercer and Maya Patel host the Daily Roundup for September 1. Get the daily rundown in your inbox - subscribe at https://thepharmacloseout.com.

Rss
Podden och tillhörande omslagsbild på den här sidan tillhör BZ Group. Innehållet i podden är skapat av BZ Group och inte av, eller tillsammans med, Poddtoppen.